Farshad Moradi Kashkooli1, Mohsen Rezaeian1, M Soltani1,2,3,4. 1. Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran, Iran. 2. Department of Electrical & Computer Engineering, University of Waterloo, Waterloo, Canada. 3. Centre for Biotechnology & Bioengineering (CBB), University of Waterloo, Waterloo, Canada. 4. Advanced Bioengineering Initiative Center, Computational Medicine Center, K. N. Toosi University of Technology, Tehran, Iran.
Abstract
Aim: In this study, the main goal was to apply a multi-scale computational model in evaluating nano-sized drug-delivery systems, following extracellular drug release, into solid tumors in order to predict treatment efficacy. Methods: The impact of several parameters related to tumor (size, shape, vessel-wall pore size, and necrotic core size) and therapeutic agents (size of nanoparticles, binding affinity of drug, drug release rate from nanoparticles) are examined in detail. Results: This study illustrates that achieving a higher treatment efficacy requires smaller nanoparticles (NPs) or a low binding affinity and drug release rate. Long-term analysis finds that a slow release rate in extracellular space does not always improve treatment efficacy compared with a rapid release rate; NP size as well as binding affinity of drug are also highly influential. Conclusion: The presented methodology can be used as a step forward towards optimization of patient-specific nanomedicine plans.
Aim: In this study, the main goal was to apply a multi-scale computational model in evaluating nano-sized drug-delivery systems, following extracellular drug release, into solid tumors in order to predict treatment efficacy. Methods: The impact of several parameters related to tumor (size, shape, vessel-wall pore size, and necrotic core size) and therapeutic agents (size of nanoparticles, binding affinity of drug, drug release rate from nanoparticles) are examined in detail. Results: This study illustrates that achieving a higher treatment efficacy requires smaller nanoparticles (NPs) or a low binding affinity and drug release rate. Long-term analysis finds that a slow release rate in extracellular space does not always improve treatment efficacy compared with a rapid release rate; NP size as well as binding affinity of drug are also highly influential. Conclusion: The presented methodology can be used as a step forward towards optimization of patient-specific nanomedicine plans.
Entities:
Keywords:
binding affinity of drug; drug release rate; drug-loaded nanocarriers; mathematical modeling of cancer nanomedicine; solid tumor; targeted drug delivery
Authors: Maddalena Grieco; Ornella Ursini; Ilaria Elena Palamà; Giuseppe Gigli; Lorenzo Moroni; Barbara Cortese Journal: Mater Today Bio Date: 2022-10-08